JAK2 and myeloproliferative neoplasm: In this regard, it has been demonstrated that JAK2-V617F-positive post-MPN sAML cell lines readily gain the ability to proliferate persistently in the presence of ruxolitinib after a long-term exposure to gradually increasing concentrations of the inhibitor [11,12,13].